Analytics24
3 September
My list
S&P7,747.7+1.06%
Nasdaq29,482.3+1.16%Stoxx6,382.6+0.32%FTSE10,831.5+0.70%Nikkei64,796.3+0.91%Hang Seng25,752.9+2.14%DXY99.00+0.01%EUR/USD1.1627+0.36%USD/JPY156.38−1.60%GBP/USD1.3527+0.32%Gold4,519.1+0.61%Silver67.37+0.59%WTI91.95+0.71%Brent95.89+0.39%10Y4.76%−3 bpVIX14.32−5.79%S&P7,747.7+1.06%Nasdaq29,482.3+1.16%Stoxx6,382.6+0.32%FTSE10,831.5+0.70%Nikkei64,796.3+0.91%Hang Seng25,752.9+2.14%DXY99.00+0.01%EUR/USD1.1627+0.36%USD/JPY156.38−1.60%GBP/USD1.3527+0.32%Gold4,519.1+0.61%Silver67.37+0.59%WTI91.95+0.71%Brent95.89+0.39%10Y4.76%−3 bpVIX14.32−5.79%S&P7,747.7+1.06%
Markets
Hypotheses · Open · Decides 31 Dec 2028 · GLP-1s and the food chain

VANQUISH names a primary read

Viking Therapeutics reports a primary weight-loss endpoint read from VANQUISH-1 or VANQUISH-2 in a public release before 31 Dec 2028.

XLinkedInEmail
Resolves by
31 Dec 2028
Confirm
The molecule trade got a number.
Kill
The trial stayed blind while the aisle moved.
Grade

Open. Resolves by 31 Dec 2028. Grades from the stated sources when the window ends.

Related writing

← Hypotheses